PHAT vs VLTO · rev $132.6M vs P/E 29, rev $5.50B
Phathom Pharmaceuticals Inc (PHAT) versus Veralto Corporation (VLTO) — a side-by-side from cached financials, not a winner call.
Phathom Pharmaceuticals Inc (PHAT) is a biotechnology company listed on US.
Veralto Corporation (VLTO) is a pollution & treatment controls company listed on US.
Latest reported PHAT revenue for 2026-06-30 was $132.6M. Net income was -$48.0M. PHAT currently screens at market cap $622.7M.
Latest reported VLTO revenue for 2025-12-31 was $5.50B. Net income was $940.0M. Revenue was up 6.0% from 2024-12-31 to 2025-12-31. VLTO currently screens at market cap $25.26B and trailing P/E 29.1.
PHAT currently screens at market cap $622.7M. VLTO currently screens at market cap $25.26B and trailing P/E 29.1.
Not investment advice. Open the PHAT and VLTO stock pages for the full models.
Not investment advice.